Anti-obesity drugs in the pipeline

NATIONAL HARBOR, Md. — In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline.

There is an “unbelievable number of anti-obesity drugs in development,” including GLP-1 receptor agonists with other incretins and appetite suppressants, Bays, chief science officer and president-elect of the Obesity Medicine Association, told Healio.

Bays, who is also the medical director and president of the Louisville Metabolic and Atherosclerosis Research Center, also discussed muscle sparing with anti-obesity drugs, how these drugs are approved and the need for better access.

“It has just been an exciting conference thus far,” he said.

Reference:

• Bays HE. Investigational anti-obesity medications in the pipeline. Presented at: Obesity Medicine 2025. April 23-27, 2025; National Harber, Md.

For more information:

Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, can be reached at primarycare@healio.com.